Full text is available at the source.
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile
Comparing the effects, safety, body processing, and brain receptor actions of serotonin-related psychedelics
AI simplified
Abstract
Psilocybin is the only psychedelic compound with established therapeutic indications for depression.
- Psychedelic compounds, including psilocybin, LSD, DMT, and 5-MeO-DMT, may have therapeutic potential as they act on serotonin 2A receptors.
- Current clinical research on these compounds is limited, with evidence primarily supporting psilocybin's efficacy for depression.
- No significant differences in psychedelic effects were observed beyond the duration of the effects among the compounds studied.
- It is unclear if the varying receptor profiles of these psychedelics influence their therapeutic potential.
- Further research is necessary to determine which compounds may be most effective for specific therapeutic applications.
AI simplified